MG
SCPS

Michael Gelband’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Michael Gelband’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-16,069
Closed -$115K – 2853
2021
Q2 		$115K Buy
+16,069
New +$114K ﹤0.01% 2124

Other funds holding SCPS

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CLOS
Compagnie Lombard Odier SCmA 1204 Geneva, Switzerland $9.25B AUM 27.04% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's SCPS Position: Q3 2021 in Review

Michael Gelband sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q3 2021, closing a stake of 16,069 shares — an estimated $115K sold.

Michael Gelband first reported a position in SCPS in Q2 2021 and held it in 1 quarter. The position peaked at $115K in Q2 2021. 14 funds tracked by Wall St. Rank hold SCPS as of Q3 2021.

  • Michael Gelband reported no remaining Scopus BioPharma Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Michael Gelband sold 16,069 Scopus BioPharma Inc. Common Stock shares in Q3 2021, an estimated $115K.
  • Michael Gelband first reported a position in Scopus BioPharma Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Michael Gelband's Scopus BioPharma Inc. Common Stock position peaked at $115K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q3 2021.

Based on ExodusPoint Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.